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Abstract
Objectives: The optimal treatment of latent autoimmune diabetes in adults (LADA) is not established.
We explored whether early insulin treatment, which has shown beneﬁcial effects in rodents and in
human pilot studies, would result in better preservation of b-cell function or metabolic control,
compared with conventional treatment.
Subjects and methods: Glucagon-stimulated C-peptide and HbAlc were evaluated at baseline and after
12, 24 and 36 months in 37 patients recently diagnosed with diabetes, aged R30 years, non-insulin-
requiring and GADAb and/or ICA positive. Twenty patients received early insulin and 17 received
conventional treatment (dietGoral hypoglycaemic agents (OHA), metformin, some and/or
sulfonylurea) and insulin when necessary.
Results: Level of metabolic control, HbAlc, was preserved in the early insulin treated, while it
signiﬁcantlydeteriorated in the conventionally treated. There wasno signiﬁcant difference between the
groups in C-peptide after 12, 24 or 36 months, or in the decline of C-peptide. Only baseline C-peptide
predicted a C-peptide of R0.5 nmol/l at 36 months. Gender, body mass index, antibody titres or HbAlc
did not inﬂuence the levels of C-peptide orHbAlc at baseline or end-of-study, or the decline in C-peptide.
Among the dietGOHA-treated, 5/17 (30%) developed insulin dependency during the follow-up.
No major hypoglycaemic events occurred.
Conclusions: Early insulin treatment in LADA leads to better preservation of metabolic control and was
safe. Superior preservation of C-peptide could not be signiﬁcantly demonstrated. Only baseline level of
C-peptide signiﬁcantly inﬂuenced C-peptide level after 3 years. Further studies exploring the best
treatment in LADA are warranted.
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Introduction
Most adults with autoimmune diabetes non-insulin-
requiringatdiagnosisbecomesowithin3–6years(1,2).
The optimal treatment for this second largest group
of patients with diabetes is still unknown (3–7). Adult
patients with autoimmune diabetes usually have larger
remaining b-cell mass at diagnosis and many develop
b-cell destruction more slowly. Latent autoimmune
diabetes in adults (LADA) is therefore a suitable group
for evaluating new therapies in autoimmune diabetes
and may also serve as a model for intervention in
classical type 1 diabetes (3, 4, 6–9).
The incidence of autoimmune diabetes is about equal
in almost all age groups (10, 11). Abrupt onset, often
with ketoacidosis, is most frequent during childhood, a
more modest onset is more frequent in adolescents
and younger adults, and among adults and elders
a slowly progressive onset, termed LADA, is frequent
(3, 4, 11, 12). Classical type 1 diabetes and LADA
patients often have normal C-peptide levels at
diagnosis, but further progressive decline occurs after
onset, and insulin dependency occurs almost inevitably
(3, 4, 8, 9, 13).
Most trials in early type 1 diabetes have been
performed in children, whose remaining b-cell mass is
limited, and short-term evaluation of intervention may
be difﬁcult also due to not infrequently occurring
remission periods (14, 15). No therapy has yet been
demonstrated to promote long-term insulin indepen-
dency (3, 5, 7, 16). Rodent studies have demonstrated
potential positive effects of insulin treatment (17, 18).
A pilot study of small doses of insulin versus
sulphonylurea (SU) to ten ICA-positive patients with
slowly progressive b-cell failure favoured insulin for the
preservation of C-peptide (19). C-peptide is the outcome
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autoimmune diabetes (20). Even modest preservation
of b-cell function has been demonstrated to have
positive effects on the frequency of hypoglycaemic
events, and on the prevalence of retinopathy (21).
Connection between glycaemic control and develop-
ment of complications is well established (21–23).
Objective
To investigate the effect of early insulin treatment in
LADA patients, for 3 years, on residual b-cell function
and metabolic control, compared with a group
initially treated with diet and/or oral hypoglycaemic
agents (OHA).
Subjects and methods
Adults, aged R30 years, diagnosed with diabetes in
Lund and Kronoberg counties in Southern Sweden,
non-insulin-requiring at diagnosis and positive to at
least one of GADAbs and/or ICAs were eligible for
participation. Two thirds had to be excluded due to
mental conditions or severe physical illness, but also
unwillingness to risk the early start of insulin injections.
The majority of the patients were randomised into two
groups, in blocks of eight, by pre-prepared closed
envelopes kept at the two hospital policlinics. However
complete strict randomisation was not possible, as
some patients refused randomisation to possible insulin
treatment before it was unavoidable. They were referred
to the control group. There were 20 patients in the
intervention group (I), treated with insulin from
baseline, starting with 2–6 units intermediate-acting
insulin at night; and 17 patients in the control group (C)
who received regular treatment with dietGOHA, mostly
metformin, and some SU (5/17; 30%). For both the
groups, goals for glucose levels were in accordance
with general guidelines (fasting plasma glucose (FPG)
4.5–7, preprandial PG 5–7 and postprandial PG
6–9 mmol/l). Decisions to increase treatment in doses,
number of doses and addition of OHAs or insulin were at
the discretion of the treating physician. If two doses/day
of intermediate-acting insulin or mix-insulin were not
satisfactory, doses of direct or rapid-acting insulin before
meals were added, resulting in 1–4 doses/day. Patients
were either treated at the hospital polyclinics or
continued at their healthcare centre.
Residual b-cell function was evaluated by glucagon-
stimulated C-peptide. Glucagon-stimulation tests were
performed at baseline and after 12, 24 and 36 months
during annual policlinic visits at the two research
clinics. After an overnight fast, C-peptide was
determined before and 6 min after i.v. injection of
1 mg glucagon (24). C-peptide was analysed by
commercial RIA (MD315, Euro-Diagnostica AB,
Malmo ¨, Sweden), total variation (sum of intra-and
inter-assay variations) 7%, reference range 0.25–1.0 nmol/l,
detection limit 0.13 nmol/l. C-peptide level, to reﬂect a
preserved normal b-cell function, was arbitrarily set at
0.5 nmol/l. ICAs were analysed with immunoﬂuores-
cence assay, with detection limit 9 JDF-U, sensitivity
100% and speciﬁcity 88%. GADabs were analysed with
radioimmuno-precipitation with lower reference limit at
an index of 0.08, corresponding to 21 WHO-U/ml,
sensitivity 70% and speciﬁcity 100%. IA-2A were
analysed with ELISA. All analyses were standardised
according to the Diabetes Antibody Standardization
Program (25, 26). Metabolic control was assessed by
HbAlc (Mono-S), and values were converted to DCCT
standard (27).
Regarding the metabolic syndrome, complete infor-
mation was available regarding only body mass index
(BMI) and prevalence of hypertension, deﬁned as blood
pressureO140/80 mmHgatthebaselinevisit,ortaking
antihypertensive medication.
All subjects provided informed consent. The study
was approved by the ethical committee of Lund
University. The study is registered in ClinicalTrials.gov
Identiﬁer: NCT01109927.
Statistical analyses
Analyses were carried out according to intention-
to-treat. For comparisons between the groups, Student’s
t-test, c
2 or Fisher’s exact test and the Mann–Whitney
U test were performed where appropriate. C-peptide and
HbAlc at baseline and after 12, 24, and 36 months were
analysed with repeated measures ANOVA using time
as covariate; for three-group analyses, ANOVA with
Bonferroni correction was performed where appropri-
ate. Risk factors and relations were analysed in several
models with simple, multiple, linear and logistic
regressions (forward stepwise, Wald). All tests were
two-sided, P!0.05 was considered signiﬁcant. SPSS
software, version 17.0 (Chicago, IL, USA), was used.
Results
For the baseline characteristics of the groups, see
Table 1. There were no signiﬁcant gender differences
in the whole study, except that in the control group
there were only men with hypertension (PZ0.03). Most
subjects were overweight since both the I and C groups
had mean BMIR27 kg/m
2. Median duration of diabetes
at inclusion in the study was 5.0 (quartiles 3.0–9.0)
months. In both the groups, 90% of the patients, 18/20
in I and 15/17 in C, completed 36 months of follow-up.
Four patients withdrew consent. Among the conven-
tionally treated (C), 30% (5/17) started insulin
treatment due to clinical necessity within 6–6–12–
18–24–30 months.
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For the levels of glucagon-stimulated C-peptide, see
Table 2 and Fig. 1. C-peptide levels were unchanged for
four patients, increased by mean 0.73 (G0.5) nmol/l
for six and declined in all others after 36 months. Mean
glucagon-stimulated C-peptide decreased signiﬁcantly
in both the groups during the 36 months (P!0.0001).
There was a signiﬁcant time trend for the decrease in
C-peptide of 0.17 nmol/l per year (PZ0.03) over 36
months without any signiﬁcant difference between the
groups. In repeated measures, ANOVA with time as
covariate, that analyses the changes in C-peptide over
time with the levels at baseline taken into account, no
differences could be found regarding mean-stimulated
C-peptide at any time point, although with the Mann–
Whitney U test the difference in C-peptide at baseline
(Cp0) was signiﬁcant, PZ0.03. There were large
variations in C-peptide levels between different individ-
uals, at all time points, within both the groups
(P!0.0001), explaining all the variation between
them (Fig. 1A and B). Cp0 explained 43% of level of
C-peptide at 36 months (Cp36), R
2 0.43 (P!0.0001).
Furthermore, age was the only other factor that had a
weak and non-signiﬁcant inﬂuence on Cp36, explaining
about 5% of Cp36, R
2 0.049 (PZ0.2). The inﬂuence of
age was eliminated when included in a multiple
regression model. Gender, baseline or end-of-study
values of BMI, titres of GADAb or ICA, HbAlc or
diabetes duration before the study start did not
inﬂuence C-peptide at end-of-study. There was no
signiﬁcant difference in the proportion of patients with
a Cp36 R0.5 nmol/l. It was 86% (13/15) in C, and
61% (11/18) in I (PZ0.13).
The odds ratio (OR) for having a Cp36 R0.5 nmol/l
was 2.4 for every increase in Cp0 with 0.10 nmol/l
(PZ0.02), and 1.06 for each increase in baseline age by
1 year (PZ0.03). If corrected for Cp0 and age, the two
factors found to have any inﬂuence on Cp36, the insulin
treated had a non-signiﬁcant OR of 2.5 (0.04–184) of
having a Cp36 of R0.5 nmol/l.
The results of levels of fasting C-peptide (FCP), when
comparing the two treatment groups (data not shown),
were in accordance with the described results of
stimulated C-peptide.
Metabolic control
Among the controls, the level of HbAlc had increased
signiﬁcantly at 36 months from 7.0 (G1.3)% to 7.5
(G1.5)% (PZ0.006) (Fig.2). In the intervention group,
there was no signiﬁcant difference between HbAlc at
baseline, 7.3 (G1.3)%, and after 36 months, 7.2
(G0.7)% (PZ0.6) (Fig. 2). For the levels of HbAlc at
baseline and during follow-up, see Table 2 and Fig. 2.
The differences between the groups in absolute levels of
HbAlc were not signiﬁcant either at baseline or after 12,
24 or 36 months. The levels of HbAlc were not
inﬂuenced by age, gender, BMI, antibody prevalences
or titres or C-peptide levels.
Table 1 Baseline characteristics of the LADA groups. Values are meanGS.D. (range), except duration, which is median.
All Intervention group Control group P value
Age (years) 54.1G14.9 (30–80) 51.0G14.3 (30–75) 57.8G15.1 (31–80) NS
Gender (men, %) 51.4 45.0 58.8 NS
Diabetes duration (months) 5.0 (1–24) 6.0 (1.5–24) 5.0 (1–22) NS
BMI (kg/m
2) 27.8G6.2 (19.4–49.5) 27.0G6.9 (19.4–49.5) 28.7G5.3 (22.0–42.2) NS
C-peptide (stimulated, nmol/l) 1.45G0.83 (0.29–3.4) 1.2G0.73 (0.29–3.0) 1.7G0.86 (0.65–3.4) 0.03
HbAlc (%) 7.2G1.3 (5.2–10.1) 7.3G1.3 (5.6–10.1) 7.0G1.3 (5.2–9.5) NS
Titre GADA (index, ref !0.08) 0.78G0.43 (0.6–1.6) 0.78G0.39 (0.06–1.6) 0.78G0.48 (0.12–1.6) NS
Titre ICA (JDF-U) 50.2G89 (0.0–449) 29.4G40.5 72.4G118 NS
Hypertension (%) 39.4 41.2 37.5 NS
BMI O25 kg/m
2 (%) 42.0 43.5 37.5 NS
HypertensionCBMI O25 kg/m
2 (%) 32.4 29.4 37.5 NS
Table 2 Levels of glucagon-stimulated C-peptide (nmol/l) and HbAlc (%, DCCT standard), for all the participants and groups.
All Intervention group Control group
MeanGS.D. Min Max MeanGS.D. Min Max MeanGS.D. Min Max
C-peptide baseline 1.45G0.8 0.29 3.4 1.2G0.7 0.29 3.0 1.7G0.9 0.65 3.4
C-peptide 12 months 1.35G0.9 0.00 3.4 1.0G0.7 0.0 3.3 1.7G0.9 0.53 3.4
C-peptide 24 months 1.17G0.8 0.00 3.6 0.80G0.6 0.0 1.8 1.5G0.9 0.37 3.6
C-peptide 36 months 0.99G0.8 0.00 3.6 0.73G0.6 0.0 2.2 1.3G0.9 0.32 3.6
HbAlc baseline 7.2G1.3 5.2 10.1 7.3G1.3 5.6 10.1 7.0G1.3 5.2 9.5
HbAlc 12 months 6.9G1.2 5.2 10.9 7.1G1.0 5.2 8.5 6.7G1.4 5.4 10.9
HbAlc 24 months 7.1G1.2 5.1 9.3 7.4G1.0 5.7 9.0 6.8G1.3 5.1 9.3
HbAlc 36 months 7.3G1.1 5.3 9.8 7.2G0.7 5.8 8.3 7.5G1.5 5.3 9.8
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At baseline, prevalences of GADAb were 94%, ICA 67%,
72% had both antibodies, 22% GADAb only and 6%
only ICA, with no signiﬁcant differences between the
two treatment groups. Of the 32 patients whose IA-2A
status was known, 7 (22%) were positive, all of them
were also positive to GADAb and all but one was positive
to ICA, meaning that 75% of all were positive to at least
two antibodies.
At baseline, mean indexes of GADAb were 0.78
(G0.39) in I, 0.78 (G0.48) in C (NS) and mean ICA
titres were 29.4 (G40) in I, 72.4 (G119) JDF-U in C
(NS). At baseline,there were no signiﬁcant differences in
the prevalences of any of the three antibodies between
the two treatment groups or between genders, different
ages, duration of diabetes before study start or levels of
BMI or HbAlc. Neither were there any signiﬁcant
differences between the groups in titres of GADAb or
ICA after 12, 24 or 36 months. The titres of GADab
or ICA were not related to patient age, gender, BMI,
diabetes duration, treatment or HbAlc at baseline or
during the follow-up. C-peptide at baseline or 36
months was not inﬂuenced by baseline titre of
GADAb, ICA or IA-2A.
Adverse events
No episodes of major hypoglycaemia were reported for
any of the patients, and only a few minor ones.
Mean weight at baseline was 77.4 (G14.5, range
57.8–110) kg in group I, and 83.0 (G17.8, range
50.8–117) kg in group C (NS); at end-of-study 79.3
(G12.4, 57.7–101) kg in I, 82.3 (G14.8, range
50.4–115) kg in C (NS). Mean weight change during
the study was 2.5 (G4.8, range K8.8 to C9.3) kg in I;
K1.0 (G10.5, range K27.3 to C16.4) kg in C (NS).
Three-group analysis and ever- versus
never-insulin treated
For the three groups, those treated with insulin from
baseline,those never treated with insulin and those who
were originally treated with dietGOHA, but had to start
insulin treatment during the study, the inﬂuences of
age, BMI, HbAlc, diabetes duration before study start or
antibody titres were analysed, with no signiﬁcant
ﬁndings except for the inﬂuence of Cp0 on Cp36. The
tests for all the relevant parameters were also carried
out with the 37 patients divided into groups of ever-
versus never-insulin treated (during the study), again
with no signiﬁcant results (PZ0.12–0.87), apart from
the signiﬁcant inﬂuence of Cp0 on Cp36 (P!0.0001).
Discussion
Few prospective intervention studies have been con-
ducted in LADA patients and there is still no general
agreement on the best treatment aimed to preserve
b-cell function (5–7, 16). There has not been any
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Figure 1 (A and B) C-peptide (nmol/l) for individual LADA subjects,
in grey, and mean for the group, in black, at baseline and after 12,
24 and 36 months. The mean decline in C-peptide during the study
was the same in both the groups, rZ0.174 and 0.174 (NS).
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Figure 2 Mean HbAlc levels (%, DCCT standard) for the two LADA
groups during 36 months. *–* The asterisks indicate that the
increase of 0.5% in HbAlc from baseline to 36 months within the
control group is signiﬁcant.
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cates comparisons and pooling of results. The most
common denominators are adult age, positivity to at
least one pancreatic autoantibody, and non-insulin
dependency at diagnosis (4). Age, BMI, duration of
diabetes and of insulin independency, which of the
antibodies that were analysed, GADAb titres and the
expression of the essential outcome variable C-peptide
vary (2, 4, 5, 28–30). A Cochrane review also noted the
heterogeneity between studies, and the conclusion about
early insulin treatment was uncertain (5).O u rs t u d y
included patients aged R30 years, non-insulin dependent
at the times of diagnosis and inclusion and positive to at
least one pancreatic autoantibody, for 75% two antibodies,
thereby fulﬁlling the main criteria for LADA (4). The
results of the study indicated that none of the baseline
parameters, except initial C-peptide level, signiﬁcantly
inﬂuenced the outcome, eliminating the importance of
several criteria in comparisons with other studies. In other
studies,patientsagedO65yearshaveoftenbeenexcluded,
but LADA exists also in these older age groups (11).
The decline in residual b-cell function was progressive
for the majority of our LADA patients, as is usual in
autoimmune diabetes (4, 8, 13, 16). We observed great
variation in the rates and magnitudes of b-cell loss
between patients and between different time periods
during the study, with no consistent patterns.
Mechanisms such as more step-wise losses due to, for
instance, partial remissions might explain this (15). The
decline in C-peptide was irrespective of age, gender, BMI,
antibody titres, HbAlc or treatment modality. The lack
of inﬂuence of BMI, age, diabetes duration and baseline
HbAlc on disease progression was also seen in a non-
interventional observation study of LADA that followed
13 Ab-positive patients by stimulated C-peptide for 2
years (16).
Similar to UKPDS, we found no association between
GADAb levels and disease progress (31), in contrast to
observational studies that described this (30, 32).W e
could not, in a number of regression analyses, deﬁne
any other factor besides Cp0 that signiﬁcantly inﬂu-
enced the level of Cp36. The signiﬁcance of initial
C-peptide level was also demonstrated in a large
Swedish study of new-onset 15–34 year olds and in
the Tokyo intervention study (28, 33). The length of our
study may explain that some patients with initially
higher levels of C-peptide, overrepresented in the control
group, by 36 months had not yet lost enough b-cell
function to be clinically insulin dependent. Some
antibody-positive patients were described to take up to
12 years to become insulin dependent, but practically
all eventually did (34).
A signiﬁcant beneﬁcial effect of early insulin treat-
ment on the preservation of b-cell function could not be
demonstrated, but level of HbAlc after 36 months was
better preserved in the insulin treated, in keeping with
observations by Chaillous et al. (16) in a smaller group
of antibody-positive patients. Incidentally, the shape of
the curve of the development of HbAlc levels over time
for the conventionally treated group in our study had a
likeness to that observed in the UKPDS (35).
Our study, as most prospective intervention studies of
LADA, was not large. The Tokyo study, with 60 patients,
found a preference for insulin treatment versus SU,
possibly due to the differences in treatment, but longer
duration of diabetes, up to 5 years without insulin
before inclusion, rendering a selection of patients with
better endogenous insulin production from the start,
would have excluded those who progressed earlier to
insulin dependence, so the trial population differed from
ours (28). Baseline level of C-peptide was an important
independent predictor of the ability to preserve a
sufﬁcient amount of C-peptide over time, just as in
our study.
Many reports end with a general recommendation of
insulin treatment in LADA, but the evidence has not
been compelling, as concluded by the 2007 Cochrane
review, which scrutinised seven insulin intervention
studies in LADA, two insulin versus SU, the rest insulin
alone versus different combinations of insulinCOHA
(5). UKPDS recorded HbAlc, weight and treatment,
randomised to insulin versus SU, and found that 60% of
the SU treated were insulin dependent after 2 years (36).
One conclusion was that SU might promote insulin
dependency and apart from not recommending SU the
Cochrane review found no preference for any special
type of treatment for the LADA group (5). In our study
after 3 years, 65% of the conventionally treated patients
were not yet treated with insulin. In contrast to both
UKPDS and the Tokyo study, only 30% of our control
patients were treated with SU, which could be of
importance for b-cell function. In another study, of 54
patients in four groups, the insulin treated, all with low
FCP, %0.3 nmol, received either insulin alone or
combined with rosiglitazone (RGZ), and the OHA
treated, all with FCP O0.3 nmol/l, received SU or RGZ
(29). The results indicated that all who received RGZ
better preserved their b-cell function.
Further considerations
To our knowledge, this study is the ﬁrst prospective
controlled European intervention study of treatment
in LADA. Differences in deﬁning the LADA population
regarding age, diabetes duration before start of
intervention, antibody prevalences and GADAb titres,
BMI and, not least, baseline levels of C-peptide, if
available, have contributed to difﬁculties in interpreting
and comparing the results of the few existing LADA
intervention studies (4, 5, 28, 29, 37). In this study,
none of these factors, except baseline level of C-peptide,
signiﬁcantly affected the outcome. The similar ﬁndings
also seen in trials of classical type 1 diabetes and
of prevention of autoimmune diabetes in high-risk
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of initial level of C-peptide on outcome level (38, 39).
We found a signiﬁcantly better preservation of
metabolic control in the early insulin treated. We also
saw a non-signiﬁcant OR favouring insulin treatment
for preservation of b-cell function, indicating the
possibility that a larger study population and/or a
longer period of follow-up might demonstrate signi-
ﬁcant preference for early insulin treatment also
regarding b-cell function.
Conclusions
This study indicated that early insulin treatment in
LADA patients lead to better preservation of level of
metabolic control, and that it was safe and well
tolerated. It could not signiﬁcantly conﬁrm better
preservation of b-cell function. The decline in
C-peptide was progressive irrespective of age, gender,
BMI, HbAlc levels and antibody titres. Only baseline
level of C-peptide signiﬁcantly inﬂuenced C-peptide level
after 3 years. Further studies exploring the best
treatment of LADA patients are warranted.
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